Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
Question
Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
Direct answer
Novartis announced that the Phase 3 HORIZON trial evaluating pelacarsen, an antisense therapy directed against lipoprotein(a), failed to demonstrate a statistically significant reduction in major adverse cardiovascular events in patients with established cardiovascular disease. Royalty Pharma, which funded $500 million of development in exchange for royalty interests, stated that structured recovery terms will allow full principal recoupment and a modest positive return, limiting credit impairment. — bearish pressure on NVS.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-05
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint”, revision 1, evidence through 2026-09-05. https://marketontology.com/catalysts/2026-09-05/novartis-phase-3-pelacarsen-trial-fails-primary-cardiovascular-endpoint-851f5c
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| NVS | ▼Bear | 1–5 days | Macro Repricing | 65 |
Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint
Novartis announced that the Phase 3 HORIZON trial evaluating pelacarsen, an antisense therapy directed against lipoprotein(a), failed to demonstrate a statistically significant reduction in major adverse cardiovascular events in patients with established cardiovascular disease. Royalty Pharma, which funded $500 million of development in exchange for royalty interests, stated that structured recovery terms will allow full principal recoupment and a modest positive return, limiting credit impairment. — bearish pressure on NVS.
Novartis announced that the Phase 3 HORIZON trial evaluating pelacarsen, an antisense therapy directed against lipoprotein(a), failed to demonstrate a statistically significant reduction in major adverse cardiovascular events in patients with established cardiovascular disease. Royalty Pharma, which funded $500 million of development in exchange for royalty interests, stated that structured recovery terms will allow full principal recoupment and a modest positive return, limiting credit impairment.
- SummaryNovartis announced that the Phase 3 HORIZON trial evaluating pelacarsen, an antisense therapy directed against lipoprotein(a), failed to demonstrate a statistically significant reduction in major adverse cardiovascular events in patients with established cardiovascular disease. Royalty Pharma, which funded $500 million of development in exchange for royalty interests, stated that structured recovery terms will allow full principal recoupment and a modest positive return, limiting credit impairment.
- NVSDirect directional or hedged short
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- NVS closes above pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- NVS price vs. pre-event level
- NVS volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growthAUTL GILD NVS
- 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growthAUTL GILD NVS
- 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500MNVS RPRX
- 2026-09-05Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary EndpointNVS RPRX
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointIONS NVS-11.45%
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointIONS NVS RPRX-11.45%
- 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500MNVS
- 2026-09-01Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS TrialsNVS
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.